Seres Therapeutics Inc (NASDAQ: MCRB) is -30.68% lower on its value in year-to-date trading and has touched a low of $0.91 and a high of $6.87 in the current 52-week trading range. The question becomes, what are the chances the stock will make a comeback and enjoy potential growth. Why not look at analysts view on what the future holds for the stock. The MCRB stock was last observed hovering at around $0.98 in the last trading session, with the day’s loss setting it -0.01%.
Currently trading at $0.97, the stock is -10.98% and -18.22% below its SMA20 and SMA50 respectively. However, with a daily trading volume of 4.17 million and changing -0.97% at the moment leaves the stock -62.88% off its SMA200. MCRB registered -83.66% loss for a year compared to 6-month loss of -70.05%. The firm has a 50-day simple moving average (SMA 50) of $1.84 and a 200-day simple moving average (SMA200) of -$2.47.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The stock witnessed a -4.85% gain in the last 1 month and extending the period to 3 months gives it a -10.14%, and is -21.10% down over the last 5 days. If we measure the stock’s price variations over the week and the month, we find that the volatility rates stand at 7.57% over the week and 7.03% over the month.
Seres Therapeutics Inc (MCRB) has around 233 employees, a market worth around $146.56M and $126.33M in sales. Profit margin for the company is -90.02%. Distance from 52-week low is 6.65% and -85.87% from its 52-week high. The company has generated returns on investments over the last 12 months (-70.03%).
Seres Therapeutics Inc quarterly earnings per share for the current quarter are estimated at -$0.35 with sales reaching $300k over the same period.The EPS is expected to shrink by -20.06% this year, but quarterly earnings will post -98.90% year-over-year. Quarterly sales are estimated to shrink -78.30% in year-over-year returns.
Seres Therapeutics Inc (MCRB) Top Institutional Holders
137 institutions hold shares in Seres Therapeutics Inc (MCRB), with institutional investors hold 63.07% of the company’s shares. The shares outstanding are 135.04M, and float is at 114.13M with Short Float at 13.66%. Institutions hold 59.48% of the Float.
The top institutional shareholder in the company is Flagship Pioneering Inc. with over 23.12 million shares valued at $110.73 million. The investor’s holdings represent 18.03% of the MCRB Shares outstanding. As of Jun 29, 2023, the second largest holder is FMR, LLC with 19.19 million shares valued at $91.9 million to account for 14.96% of the shares outstanding. The other top investors are Federated Hermes, Inc. which holds 11.39 million shares representing 8.89% and valued at over $54.58 million, while State Street Corporation holds 6.68% of the shares totaling 8.56 million with a market value of $41.03 million.
Seres Therapeutics Inc (MCRB) Insider Activity
The most recent transaction is an insider sale by Shaff Eric D.,the company’sCEO and President. SEC filings show that Shaff Eric D. sold 11,549 shares of the company’s common stock on Feb 16 ’24 at a price of $1.08 per share for a total of $12473.0. Following the sale, the insider now owns 0.14 million shares.
Seres Therapeutics Inc disclosed in a document filed with the SEC on Feb 16 ’24 that Ege David sold a total of 5,010 shares of the company’s common stock. The trade occurred on Feb 16 ’24 and was made at $1.08 per share for $5411.0. Following the transaction, the insider now directly holds 73856.0 shares of the MCRB stock.
Still, SEC filings show that on Feb 16 ’24, von Moltke Lisa disposed off 4,400 shares at an average price of $1.08 for $4752.0. The insider now directly holds 16,988 shares of Seres Therapeutics Inc (MCRB).
